InvestorsHub Logo
Followers 49
Posts 5072
Boards Moderated 0
Alias Born 03/23/2014

Re: None

Friday, 11/08/2019 12:55:31 PM

Friday, November 08, 2019 12:55:31 PM

Post# of 704279
Marnix Bosch speaking about DCVax in about a month:
December 10-11, 2019
Boston, MA

11:40 am DCVax Technology: Leveraging Activated Dentritic Cells in Clinical 40 for GBM
Marnix Bosch
CTO, Northwest Biotherapeutics
Synopsis
Exploring the history, biology and development of the platform technology DCVax
Outlining the key aspects of the DCVax technology that contribute to the positive clinical results
Designed to mobilize the entire immune system
Designed to target not just one but the full set of biomarkers on the patient’s tumor
DCVax is personalized, and targets the particular biomarkers expressed on that patient’s tumor
Pinpointing highs and lows of clinical development to date



Glioblastoma Drug Development Summit
https://glioblastoma-drugdevelopment.com/about/agenda/day-two/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News